May 15, 2018 / 1:12 PM / a month ago

BRIEF-Immune Pharma Presents Positive Results From Phase 2 Trial Of Bullous Pemphigoid Treatment

* IMMUNE PHARMACEUTICALS PRESENTS UPDATED POSITIVE RESULTS FROM PHASE 2 TRIAL OF BERTILIMUMAB IN BULLOUS PEMPHIGOID

* IMMUNE PHARMACEUTICALS INC - POSITIVE DATA SUPPORT COMPANY’S PLANS TO COMMENCE PIVOTAL REGISTRATION STUDY IN 2019

* IMMUNE PHARMACEUTICALS INC - RESULTS FROM ALL SUBJECTS CONFIRM “EXCELLENT” SAFETY AND TOLERABILITY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below